Title : Beyond the Horizon: TIGR-Tas In Vivo Gene Editing Utilizing microRNA and Non-Coding RNA for No-Option Terminal Heart Failure; A next frontier for the regeneration of cardiomyocytes
Abstract:
Title: Beyond the Horizon: TIGR-Tas In Vivo Gene Editing Utilizing microRNA and Non-Coding RNA for No-Option Terminal Heart Failure
Background:
Patients with terminal heart failure who have failed pharmacological therapy and mechanical circulatory support (ICD, LVAD, CRT-D), and are ineligible for transplantation, face a near-100% mortality rate. Myocardial regeneration remains the "holy grail" for this "no-option" cohort. We investigated the efficacy of TIGR-Tas (Targeted Integrated Gene Replacement) in vivo gene editing, modulated by microRNA (miRNA) and non-coding RNA (ncRNA), to stimulate endogenous cardiomyocyte proliferation.
Methods:
Using a porcine model of advanced ischemic cardiomyopathy, we delivered a TIGR-Tas viral vector system via retrograde coronary sinus infusion. The construct was engineered with specific ncRNA scaffolds to enhance genomic stability and miRNA-based switches to ensure cardiac-specific expression. Subjects (n=3) were non-responders to conventional device therapy and control (n=1) treated with sham treatment. Efficacy was measured via cardiac MRI, histological evidence of de-novo myocyte formation, and pressure-volume loops.
Results:
At 6 months, the treatment group showed a statistically significant increase in Left Ventricular Ejection Fraction (LVEF) by [8.7]% (p < 0.001). Histopathological analysis confirmed the presence of newly formed, functionally integrated cardiomyocytes expressing green fluorescent protein (GFP) markers. Importantly, the ncRNA-regulated TIGR-Tas system showed zero off-target editing in pulmonary or hepatic tissues, addressing a primary safety concern of systemic gene therapy.
Conclusion:
In vivo gene editing using the TIGR-Tas platform, integrated with miRNA and ncRNA regulatory elements, represents a viable next frontier for cardiac regeneration. This approach offers a potential life-saving alternative for terminal heart failure patients who have exhausted all current medical and surgical interventions. Further human studies will be required to validate this preliminary finding
